Results 81 to 90 of about 18,807 (182)

Rapid prediction of inducible clarithromycin resistance in Mycobacterium abscessus

Molecular and Cellular Probes, 2015
We have developed a single tube TaqMan(®) real-time PCR assay that differentiates the full-length and truncated erm(41) gene to predict inducible resistance to clarithromycin in Mycobacterium abscessus. A study of 87 clinical isolates found this assay to be 90.8% concordant to conventional drug susceptibility testing results for the prediction of ...
Yan Chun, Zhu, Kara K, Mitchell, Elizabeth J, Nazarian, Vincent E, Escuyer, Kimberlee A, Musser   +4 more
openaire   +2 more sources

Multi‐Targeting Carnosic Acid Kills Drug‐Resistant Helicobacter pylori With Narrow‐Spectrum Activity

Advanced Science, Volume 13, Issue 50, 7 September 2026.
Carnosic acid selectively eradicates drug‐resistant Helicobacter pylori through a multi‐targeted mechanism involving urease inhibition, membrane disruption, and biofilm eradication. It exhibits no detectable resistance, potent in vivo efficacy, and minimal impact on gut microbiota, positioning it as a promising narrow‐spectrum lead compound against ...
Yuefan Bai, Hongming Huang, Xudong Hang, Shanwei Hu, Qian Tong, Jingchen Xu, Jia Jia, Hongkai Bi   +7 more
wiley   +1 more source

Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex

PLOS ONE, 2015
Clarithromycin was considered the cornerstone for the treatment of Mycobacterium abscessus complex infections. Genetic resistance mechanisms have been described and many experts propose amikacin as an alternative. Nevertheless, clarithromycin has several advantages; therefore, it is necessary to identify the non-functional erm(41) allele to determine ...
Rubio, Marc, March, Francesca, Garrigó i Fullola, Montserrat, Moreno, Carmen, Español, Montserrat, Coll Figa, Pedro   +5 more
openaire   +6 more sources

Current Helicobacter pylori Diagnostics: Established Methods, Resistance Testing, and Emerging Approaches

JGH Open, Volume 10, Issue 9, September 2026.
ABSTRACT Aims Accurate diagnosis of Helicobacter pylori infection is required to detect active infection, confirm eradication, assess gastric pathology when indicated, and obtain antimicrobial resistance information that may guide treatment. This review evaluates the clinical roles, limitations, and implementation maturity of established, molecular ...
Tianhua Tang, Erwin A. Paz, Kan Yu, Khui Hung Lee, Chin Yen Tay, Jingjing Wang, Barry James Marshall, Linli Hu, Wanting Fu, Ziyao Yang   +9 more
wiley   +1 more source

Influence of Host Factors on Drug Resistance of Helicobacter Pylori Infection

Xiehe Yixue Zazhi
ObjectiveTo analyze the host factors affecting the drug resistance of Helicobacter pylori (Hp).MethodsPatients with Hp infection were consecutively recruited in the Affiliated Suzhou Hospital of Nanjing Medical University from November 2021 to October ...
CHEN Chen, WU Ying, HUA Xian, LU Jinnan, LI Yi, ZHAO Chunhua, MIN Han   +6 more
doaj   +1 more source

Population Pharmacokinetic Analysis of Brensocatib in Adult and Adolescent Patients With Non‐Cystic Fibrosis Bronchiectasis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT Brensocatib, a competitive and reversible oral DPP1 inhibitor, at 10 and 25 mg significantly reduced pulmonary exacerbation burden, and 25 mg also reduced lung function decline vs. placebo in patients with non‐cystic fibrosis bronchiectasis, hereafter bronchiectasis, in ASPEN (NCT04594369).
Helen Usansky, Anthony Cammarata, ChongHua Li, Sam Au Yeung, Christopher M. Rubino, Lin Wang, Ariel Teper, Carlos Fernandez, Kevin Mange   +8 more
wiley   +1 more source

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Early clinical development of anticancer drugs traditionally focused on exploring candidate treatments in patients. For instance, due to their cytotoxic action, administration of chemotherapies to healthy volunteers (HVs) for evaluation of their pharmacokinetic profiles was not considered feasible nor ethical from a safety and tolerability ...
Aernout D. van Haarst, Sabina Paglialunga, Ziv Machnes, Ikuo Yamamiya, Nanae Hangai, Aram Oganesian   +5 more
wiley   +1 more source

Population‐Level Trends in Gastric Cancer Mortality and Incidence After Expansion of Japanese National Health Insurance Coverage for Helicobacter pylori Eradication: A Descriptive Time‐Trend Study

Helicobacter, Volume 31, Issue 5, September/October 2026.
ABSTRACT Background In February 2013, Japanese national health insurance coverage for Helicobacter pylori eradication was expanded to patients with H. pylori‐positive, endoscopically diagnosed chronic gastritis. This policy broadened access to eradication treatment, but its relationship with subsequent population‐level gastric cancer trends requires ...
Masahiro Asaka, Tokuma Tanuma, Akiko Kowada, Shouji Matsushima, Kozo Akino   +4 more
wiley   +1 more source

Effects of In Vitro Antibiotic Resistance on Treatment: Bismuth-Containing Regimens

Canadian Journal of Gastroenterology, 2000
Bismuth compounds remain useful for Helicobacter pylori eradication therapy. These include colloidal bismuth subcitrate (CBS), bismuth subsalicylate (BSS) and, most recently, ranitidine bismuth citrate (RBC).
Naoki Chiba
doaj   +1 more source

Molecular mechanism of the resistance of Helicobacter pylori to clarithromycin

World Chinese Journal of Digestology, 2003
AIM: To investigate the resistance mechanism of Hp to clarithromycin. METHODS: With E-test method, we examined the minimal inhibitory concentration (MIC) to clarithromycin of 35 Hp clinical isolates. Resistance strains were defined when MIC 8 mg/L. Extract the DNA from the bacteria with the phenolchloroform extraction method. Then amplify the fragments
Qing Hao, Yan Li, Hong Gao, Xian-Zhong Zhang   +3 more
openaire   +1 more source